FY2025 EPS Estimates for Replimune Group Cut by Wedbush

Replimune Group, Inc. (NASDAQ:REPL) – Equities research analysts at Wedbush cut their FY2025 earnings per share estimates for Replimune Group in a research note issued on Wednesday, February 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($3.07) for the year, down from their previous forecast of ($2.91). The consensus estimate for Replimune Group’s current full-year earnings is ($2.88) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.93) EPS.

REPL has been the topic of several other research reports. Jefferies Financial Group lifted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. HC Wainwright raised their price target on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group currently has a consensus rating of “Buy” and a consensus target price of $19.29.

Replimune Group Trading Down 0.5 %

NASDAQ:REPL opened at $14.03 on Monday. The company’s 50 day moving average is $12.57 and its 200-day moving average is $11.77. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The firm has a market cap of $959.93 million, a price-to-earnings ratio of -4.60 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09).

Insider Activity at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Baker BROS. Advisors LP lifted its holdings in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after acquiring an additional 1,000,000 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock worth $132,761,000 after purchasing an additional 1,083,633 shares during the period. Redmile Group LLC lifted its stake in Replimune Group by 2.6% during the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock worth $59,406,000 after purchasing an additional 124,344 shares during the period. Vanguard Group Inc. boosted its holdings in Replimune Group by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company’s stock valued at $43,546,000 after purchasing an additional 129,601 shares in the last quarter. Finally, Braidwell LP grew its stake in shares of Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.